[go: up one dir, main page]

PE20020298A1 - Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1 - Google Patents

Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1

Info

Publication number
PE20020298A1
PE20020298A1 PE2001000533A PE2001000533A PE20020298A1 PE 20020298 A1 PE20020298 A1 PE 20020298A1 PE 2001000533 A PE2001000533 A PE 2001000533A PE 2001000533 A PE2001000533 A PE 2001000533A PE 20020298 A1 PE20020298 A1 PE 20020298A1
Authority
PE
Peru
Prior art keywords
triaza
decan
ona
spiro
phenyl
Prior art date
Application number
PE2001000533A
Other languages
English (en)
Inventor
Guido Galley
Sabine Kolczewski
Torsten Hoffmann
Thierry Godel
Stephan Roever
Annick Goergler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020298A1 publication Critical patent/PE20020298A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA DE FORMULA I DONDE R1 ES H, ALQUILO, ALQUENILO, FENILO, (CH2)m-HETEROCICLO, (CH2)m-HETEROARILO, (CH2)mCONRR', ENTRE OTROS; R2 ES H, ALQUILO, HALOGENO, ALCOXILO; R3 ES ALQUILO, ALCOXILO, HALOGENO, CF3; R Y R' SON H, ALQUILO; X ES N, C=, CH; X1 Y X2 SON H, OH, ALCOXILO O JUNTOS SON OXO; Y1 Y Y2 SON H, ALQUILO, (CH2)m-FENILO O JUNTOS SON OXO; Z ES ENLACE, CH2, CO; m ES 0-4; n ES 2-3; n' ES 0-2. SON COMPUESTOS PREFERIDOS 8-(3,5-BIS-TRIFLUOROMETIL-BENZOIL)-3-(4,6-DIMETOXI-1,3,5)TRIACIN-2-IL)-1-IL)-1-FENIL-1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA; 8-(3,5-BIS-TRIFLUOROMETIL-BENZOIL)-1-(2-CLORO-FENIL)-3-(4,6-DIMETOXI-[1,3,5]TRIACIN-2-IL)-1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA, ENTRE OTROS; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS DE RECEPTORES NK-1 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL COMO DEPRESION, EMESIS
PE2001000533A 2000-06-08 2001-06-07 Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1 PE20020298A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00112285 2000-06-08

Publications (1)

Publication Number Publication Date
PE20020298A1 true PE20020298A1 (es) 2002-04-17

Family

ID=8168940

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000533A PE20020298A1 (es) 2000-06-08 2001-06-07 Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1

Country Status (17)

Country Link
US (1) US6482829B2 (es)
EP (1) EP1292596B1 (es)
JP (1) JP4245348B2 (es)
KR (1) KR100518198B1 (es)
CN (1) CN1261433C (es)
AR (1) AR028683A1 (es)
AT (1) ATE381565T1 (es)
AU (2) AU2001267513B2 (es)
BR (1) BR0111538A (es)
CA (1) CA2411716C (es)
DE (1) DE60131971T2 (es)
ES (1) ES2296761T3 (es)
MX (1) MXPA02012001A (es)
PE (1) PE20020298A1 (es)
UY (1) UY26754A1 (es)
WO (1) WO2001094346A1 (es)
ZA (1) ZA200209488B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009369B1 (ru) 2002-09-09 2007-12-28 Янссен Фармацевтика, Н.В. Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
US7498323B2 (en) * 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
BRPI0418375A (pt) * 2004-01-08 2007-05-22 Hoffmann La Roche derivados de diaza-espiropiperidina
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
KR101355064B1 (ko) * 2005-03-03 2014-01-24 얀센 파마슈티카 엔.브이. 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20090099186A1 (en) * 2005-10-11 2009-04-16 Leonid Beigelman Inhibitors of viral replication
EA200801492A1 (ru) * 2005-11-01 2008-10-30 Транстек Фарма Фармацевтическое применение замещенных амидов
EA200801243A1 (ru) * 2005-11-01 2008-10-30 Транстек Фарма Фармацевтическое применение замещенных амидов
WO2007065256A1 (en) * 2005-12-06 2007-06-14 Virochem Pharma Inc. Novel spiropiperidine compounds and methods for the modulation of chemokine receptor activity
GB0601402D0 (en) * 2006-01-24 2006-03-08 Syngenta Participations Ag Chemical Compounds
CA2646588A1 (en) * 2006-03-21 2007-09-27 High Point Pharmaceuticals, Llc Adamantane derivatives for the treatment of the metabolic syndrome
PL3412290T3 (pl) 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US8053447B2 (en) 2006-04-07 2011-11-08 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
CA2655282A1 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted piperidine carboxamides
AU2007260984A1 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
CA2657078A1 (en) * 2006-07-13 2008-01-17 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
US20080016751A1 (en) * 2006-07-20 2008-01-24 Steven Frisch Rodent trap with calming agent
MX2009005641A (es) 2006-11-28 2009-06-05 Janssen Pharmaceutica Nv Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona.
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP2010519239A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのｎ−アドマンチルベンザミド
EP2125704A1 (en) * 2007-02-23 2009-12-02 High Point Pharmaceuticals, LLC N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2010519242A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規化合物
ZA200904916B (en) 2007-02-23 2010-09-29 High Point Pharmaceuticals Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
AU2007349112A1 (en) * 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１ベータ−ｈｓｄ１活性化合物
CN101679430B (zh) * 2007-04-09 2013-12-25 詹森药业有限公司 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
US20100137377A1 (en) * 2007-04-11 2010-06-03 Soren Ebdrup Et Al Novel compounds
WO2008134221A1 (en) * 2007-04-24 2008-11-06 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
AU2010260381B2 (en) 2009-06-16 2013-10-24 Merck Sharp & Dohme Corp. Substituted -1,3,8-triazaspiro[4.5]decane-2,4-diones
IN2012DN01661A (es) * 2009-07-24 2015-06-05 Univ Vanderbilt
EA028869B1 (ru) 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
CA2850597A1 (en) 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
PT3305285T (pt) 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
WO2017005583A1 (en) * 2015-07-03 2017-01-12 F. Hoffmann-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3414247B1 (en) 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
AU2021325024A1 (en) * 2020-08-11 2023-04-13 Board Of Trustees Of Michigan State University Proteasome enhancers and uses thereof
KR20250001677A (ko) * 2023-06-29 2025-01-07 한국과학기술연구원 신규한 포화헤테로고리가 치환된 헤테로아릴-카르보노히드라조노일 디시아나이드 화합물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416193A (en) 1993-04-30 1995-05-16 Pfizer Inc. Coupling reagent and method
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
KR100286412B1 (ko) 1993-12-29 2001-04-16 더블유. 지. 콜 치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
PL326353A1 (en) 1995-10-17 1998-09-14 Astra Pharma Prod Pharmaceutically active quinozolinic compounds
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof

Also Published As

Publication number Publication date
ATE381565T1 (de) 2008-01-15
EP1292596B1 (en) 2007-12-19
EP1292596A1 (en) 2003-03-19
DE60131971T2 (de) 2008-12-04
JP2003535863A (ja) 2003-12-02
ES2296761T3 (es) 2008-05-01
CN1436188A (zh) 2003-08-13
DE60131971D1 (de) 2008-01-31
CA2411716A1 (en) 2001-12-13
KR100518198B1 (ko) 2005-10-04
CN1261433C (zh) 2006-06-28
UY26754A1 (es) 2001-12-28
AU2001267513B2 (en) 2006-03-16
US6482829B2 (en) 2002-11-19
JP4245348B2 (ja) 2009-03-25
CA2411716C (en) 2010-06-22
KR20030016283A (ko) 2003-02-26
MXPA02012001A (es) 2003-04-22
AU6751301A (en) 2001-12-17
US20020006932A1 (en) 2002-01-17
BR0111538A (pt) 2003-07-01
AR028683A1 (es) 2003-05-21
WO2001094346A1 (en) 2001-12-13
ZA200209488B (en) 2004-02-23

Similar Documents

Publication Publication Date Title
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
CY1110382T1 (el) Πυραζινο υποκατεστημενες αρυλοβενζοδιαζεπινες
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20020915A1 (es) Diaminotiazoles como inhibidores de quinasas dependientes de ciclina
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
BG105781A (en) Piperidine, tetrahydropyridine and piperazine derivatives, their preparartion and use
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
PE20021041A1 (es) DERIVADOS DE DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-0NA COMO ANTAGONISTAS II mGLUR2
ATE358482T1 (de) 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
PE20050489A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
PE20011114A1 (es) Decahidro-isoquinolinas
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
PE75199A1 (es) Derivado de quinolina util como antagonista de neuroquinina
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
ATE125808T1 (de) Indolederivate und ihre verwendung als serotonin- antagoniste.
AR034350A1 (es) Indazoles e indoles fusionados, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento para el tratamiento de glaucoma
YU26499A (sh) Derivati diaza-spiro/3,5/nonana

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed